

# David W Schultz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/631479/publications.pdf>

Version: 2024-02-01

19  
papers

1,591  
citations

687220

13  
h-index

839398

18  
g-index

19  
all docs

19  
docs citations

19  
times ranked

2153  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. <i>Lancet Neurology</i> , The, 2008, 7, 299-309.	4.9	971
2	Restenosis and risk of stroke after stenting or endarterectomy for symptomatic carotid stenosis in the International Carotid Stenting Study (ICSS): secondary analysis of a randomised trial. <i>Lancet Neurology</i> , The, 2018, 17, 587-596.	4.9	114
3	EPITHET. <i>Stroke</i> , 2011, 42, 59-64.	1.0	90
4	Urinary p75 <sup>ECD</sup> . <i>Neurology</i> , 2017, 88, 1137-1143.	1.5	84
5	The Extracellular Domain of Neurotrophin Receptor p75 as a Candidate Biomarker for Amyotrophic Lateral Sclerosis. <i>PLoS ONE</i> , 2014, 9, e87398.	1.1	57
6	Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort. <i>BMJ Open</i> , 2016, 6, e012054.	0.8	48
7	A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of <i>Reldesemtiv</i> In Patients With ALS. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 287-299.	1.1	42
8	Genome-wide Meta-analysis Finds the ACSL5-ZDHHC6 Locus Is Associated with ALS and Links Weight Loss to the Disease Genetics. <i>Cell Reports</i> , 2020, 33, 108323.	2.9	41
9	Motor neurone disease: progress and challenges. <i>Medical Journal of Australia</i> , 2017, 206, 357-362.	0.8	28
10	CLIPPERS: Induction and maintenance of remission using hydroxychloroquine. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e56.	3.1	21
11	Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. <i>Biomarker Research</i> , 2019, 7, 3.	2.8	19
12	Safety and efficacy of dimethyl fumarate in ALS: randomised controlled study. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1991-1999.	1.7	18
13	Transient Changes on Brain Magnetic Resonance Imaging in a Patient With Sturge-Weber Syndrome Presenting With Hemiparesis. <i>Neurologist</i> , 2009, 15, 351-354.	0.4	15
14	Urinary neopterin: A novel biomarker of disease progression in amyotrophic lateral sclerosis. <i>European Journal of Neurology</i> , 2022, 29, 990-999.	1.7	14
15	Recanalisation and outcome cerebral venous thrombosis. <i>Journal of Clinical Neuroscience</i> , 1996, 3, 133-138.	0.8	12
16	Functional characterisation of the amyotrophic lateral sclerosis risk locus GPX3/TNIP1. <i>Genome Medicine</i> , 2022, 14, 7.	3.6	12
17	MiNDAUS partnership: a roadmap for the cure and management of motor Neurone disease. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 321-328.	1.1	4
18	Factors contributing to delays in the diagnosis of motor neuron disease – A South Australian study. <i>Journal of the Neurological Sciences</i> , 2019, 407, 116540.	0.3	1

#	ARTICLE	IF	CITATIONS
19	Theme 10 Disease stratification and phenotyping of patients. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 289-300.	1.1	0